Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Alcon

Status and phase: Completed; Phase 4

Conditions: Bacterial Conjunctivitis

Treatments: Drug: VIGAMOX

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00312338

CMS-05-11

Details and patient eligibility

About

Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora

Enrollment: 137 patients

Sex: All

Ages: 1 to 13 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients from 1 to 13 years of age that have diagnosis of bacterial conjunctivitis in either or both eyes (for < 3 days duration) based on clinical observation; matched healthy controls

Exclusion criteria

• Cannot have had bacterial conjunctivitis symptoms as reported by parent for > 2 days

Trial design

137 participants in 2 patient groups

Infected Patient treated with Vigamox

Experimental group

Description:

Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.

Treatment:

Drug: VIGAMOX

Healthy Subjects

No Intervention group

Description:

Healthy Subjects receiving no treatment